PROGENITER is a University of British Columbia-affiliated, nationally recognized, multi-year research program to enable the rapid design, engineering, and production of antibody leads against present and future viral diseases to ensure that Canada is prepared for the next pandemic. PROGENITER is a key component of Canada’s Immuno-Engineering and Biomanufacturing Hub (CIEBH). Our interdisciplinary team of researchers, students, staff and industry partners work together to discover, test and advance therapeutics targeting infectious diseases at an accelerated pace. This mission aligns with CIEBH’s vision for rapidly responding to new health threats, and with Canada’s Biomanufacturing and Life Sciences Strategy (BLSS).

Canada’s Immuno-Engineering and Biomanufacturing Hub (CIEBH) is bringing together a coalition of partners to accelerate the development and manufacturing of lifesaving medicines for BC and Canada. Led by the University of British Columbia (UBC), CIEBH is one of five national research hubs established through the integrated Canada Biomedical Research Fund (CBRF) and Biosciences Research Infrastructure Fund (BRIF) competition.

CIEBH is pursuing an integrated program of biomedical research and talent development, along with building associated infrastructure to support the development and manufacturing of medical treatments in BC and Canada. The Hub will be a strategic partner that facilitates connections between industry, academia, governments and healthcare institutions.

CIEBH’s vision is to make Canada a global epicentre for developing next-generation immune-based therapeutics that can be rapidly produced domestically, using the latest innovations in biomanufacturing, so that Canada is prepared for the next pandemic and other health threats.